DPP4 and diabetic ketoacidosis: Clinical trials have reported a higher incidence of diabetic ketoacidosis (DKA) among patients using SGLT2 inhibitors, including dapagliflozin, than in those using dipeptidyl-peptidase IV (DPP-4) drugs [9,10].